C4 Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
C4 Therapeutics tiene unos fondos propios totales de $216.0M y una deuda total de $0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son $333.0M y $117.0M respectivamente.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$253.68m |
| Equity | US$246.11m |
| Total liabilities | US$130.34m |
| Total assets | US$376.45m |
Recent financial health updates
No updates
Recent updates
C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
Mar 01Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
Feb 29
C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Feb 24New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Nov 03Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week
May 14C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors
Sep 29C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M
Aug 04Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00
May 10C4 Therapeutics: Poor Data Destroyed Preclinical Promise
May 04C4 Therapeutics closes $181M capital raise
Jun 21C4 Therapeutics gets dosing underway in early-stage CFT7455 lymphoma trial
Jun 14C4 Therapeutics nears three-month high on pre-clinical data for lung cancer therapy
Jun 07Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%
Jun 02C4 Therapeutics to advance CFT8919 into IND-enabling studies
May 26Read This Before Selling C4 Therapeutics, Inc. (NASDAQ:CCCC) Shares
Mar 15Financial Position Analysis
Pasivos a corto plazo: CCCCLos activos a corto plazo ($223.7M) de la empresa superan a sus pasivos a corto plazo ($30.3M).
Pasivo a largo plazo: CCCCLos activos a corto plazo ($223.7M) superan a sus pasivos a largo plazo ($86.7M).
Debt to Equity History and Analysis
Nivel de deuda: CCCC está libre de deudas.
Reducción de la deuda: CCCC no tenía deudas hace 5 años.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Cash runway estable: CCCC tiene suficiente margen de tesorería para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: CCCC dispone de suficiente liquidez para 1.5 años si el flujo de caja libre sigue reduciéndose al ritmo histórico de 38% cada año.